Background: Cancer-related neuropathic pain (CR-NP) is challenging to manage, and the effectiveness of corticosteroids remains underexplored. Objectives: This study investigated the analgesic and functional benefits of corticosteroids in CR-NP. Methods: This multicenter, prospective observational study enrolled patients with CR-NP who initiated or escalated corticosteroid therapy. Pain intensity and daily activities were assessed at baseline (T0), 72 (T1), and 168 h (T2). A paired-samplet-test compared pain intensity changes. Linear regression analysis examined the association between changes in opioid daily dose and pain intensity, while Pearson’s correlation coefficient assessed the relationship between changes in daily activities and pain intensity. Results: In total, 107 patients were consecutively enrolled. The mean worst pain intensity decreased from 8.2 ± 1.9 at T0 to 5.2 ± 2.9 at T1 and further to 4.4 ± 3.0 at T2. No significant correlation was found between changes in opioid daily dose and pain intensity. However, daily activities improved significantly in correlation with pain reduction (r = −0.36,p< 0.01). Over 75% of patients reported satisfaction with CR-NP management. Adverse events occurred in 21 cases and were generally mild. Conclusions: Corticosteroids provided rapid and considerable analgesic and functional benefits for patients with CR-NP in this observational setting; further validation through comparative controlled studies is required.
背景：癌症相关性神经病理性疼痛（CR-NP）的治疗具有挑战性，而皮质类固醇的疗效尚未得到充分探讨。目的：本研究旨在探讨皮质类固醇在CR-NP中的镇痛及功能改善作用。方法：这项多中心前瞻性观察性研究纳入了开始或增加皮质类固醇治疗的CR-NP患者。分别在基线（T0）、72小时（T1）和168小时（T2）评估疼痛强度和日常活动能力。采用配对样本t检验比较疼痛强度变化，线性回归分析考察阿片类药物日剂量变化与疼痛强度的关联，皮尔逊相关系数评估日常活动变化与疼痛强度的关系。结果：共连续纳入107例患者。最严重疼痛强度平均值从T0时的8.2±1.9降至T1时的5.2±2.9，并在T2时进一步降至4.4±3.0。阿片类药物日剂量变化与疼痛强度无显著相关性。然而，日常活动能力随疼痛减轻显著改善（r=-0.36，p<0.01）。超过75%的患者对CR-NP管理表示满意。共发生21例不良事件，总体程度轻微。结论：在此观察性研究背景下，皮质类固醇为CR-NP患者提供了快速且显著的镇痛及功能改善效益；仍需通过对照研究进一步验证。
肿瘤(癌症)患者之家